Ablaze Pharmaceuticals

Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company founded in 2011 with a mission to revolutionize the targeted radiotherapy landscape in China. The company has garnered attention for its partnership with RayzeBio, Inc., a leading radiopharmaceutical firm based in San Diego, CA. This strategic alliance has granted Ablaze exclusive rights for development and commercialization of a range of RayzeBio’s products in the greater China region. With a focus on the burgeoning market for targeted radiopharmaceutical therapies (TRT), Ablaze is poised to emerge as a pioneering force in this sector in China by collaborating with key partners both domestically and internationally. The latest milestone for Ablaze Pharmaceuticals was the $75.00M Series A investment on 29 November 2021, with a consortium of prominent investors including Vivo Capital, AdvanTech Capital, Nan Fung Life Sciences, Samsara BioCapital, VenBio Partners, Pivotal bioVenture Partners China, Venrock Healthcare Capital Partners, and RAYZ Investments. Ablaze Pharmaceuticals' commitment to advancing innovative radiopharmaceutical therapies in China positions it as a compelling prospect for investment in the biotechnology and pharmaceutical industries. For more information, please visit www.ablazepharma.com.